Plasma Fractionation Market

Plasma Fractionation Market Outlook (2022-2032)

The plasma fractionation market reached a valuation of US$ 32 Billion by 2022. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 7.3% CAGR, reaching US$ 65 Billion. Plasma fractionation is the process of converting donated plasma into life-saving treatments and pharmaceutical compounds.

Plasma fractionation uses mechanical separation methods such as centrifugation, depth filtration, precipitation, and chromatography to separate plasma into specific proteins or plasma fractions. Several current fractionation procedures extract particular therapeutic proteins using alcohol concentrations, time, temperature, and pH.

Increasing technological complexity and the introduction of in-process viral reduction therapies have led in the creation of novel protein therapeutics as well as improvements in product purity and quality throughout the years.

Protein products derived from human plasma are an important class of medicines that are widely utilized to prevent, manage, and cure life-threatening illnesses such as infections, congenital deficits, uncommon blood disorders, immunologic disorders, and autoimmune disorders. One of the primary reasons driving market expansion is a large increase in the prevalence of these illnesses among a significant portion of the worldwide population.

Furthermore, manufacturers are creating plasma fractionation with extra safety features as a result of the introduction of severe rules and standard controls and settings by regulatory authorities in several countries on biological product quality assurance.

Market participants are funding research and development (R&D) operations to expand plasma manufacturing technology in order to increase product efficacy and improve recovery of immunoglobulin G (IgG) in order to isolate novel plasma proteins.

Furthermore, they are working on creating low-cost viral inactivation and processing technologies that will allow them to securely use local plasma resources. This, together with the growing need to enhance yield, maintain process economics, and handle expanding regulatory requirements, is expected to create a positive market picture in the upcoming years.

Report Attribute	Details
Anticipated Base Year Value (2022)	US$ 32 Billion
Expected Market Value (2032)	US$ 65 Billion
Global Growth Rate (2022-2032)	7.3% CAGR
Prominent Plasma Fractionation Service Players	Grifols S.A. CSL Limited Takeda Pharmaceutical Company Limited Octapharma AG Kedrion S.p.A LFB S.A. Biotest AG Sanquin Bio Products Laboratory Ltd. Intas Pharmaceuticals Ltd

2017-2021 Revenue Analysis of Plasma Fractionation Market vs. Growth Outlook 2022-2032

According to Fact.MR, the global market for plasma fractionation expanded at under 6% CAGR from 2017 to 2021. The prevalence of respiratory diseases, alpha-1-antitrypsin deficiency, rising geriatric population, expanding use of immunoglobulins in various therapeutic fields, advancements in plasma collection (number of plasma collection centers), and rising geriatric population are all contributing to the rapid growth of the global plasma fractionation.

Technology progress has led to a surge in immunological illness diagnoses over the past several years, which is projected to fuel market expansion. Another important element driving the expansion of the plasma fractionation market globally is the various product improvements made by top manufacturers.

The neurology segment is valued at the highest percentage. The efficiency of IVIg in treating numerous illnesses of the peripheral and central nervous systems, as well as its reaction in a shorter time than steroids or oral immunosuppressants, are credited with the segment's expansion. Based on the aforementioned trends, the global market Plasma Fractionation is poised to surge at a 7.3% CAGR, reaching US$ 65 Billion by 2032.

Key Market Drivers Influencing Plasma Fractionation Industry Expansion

Rising Demand for Immunoglobulins to Foster Market Growth Prospects

Immunoglobulins are used as the first line of therapy for many immunologic, neurological, and hematologic illnesses. The most common application of immunoglobulin therapy is the treatment of early immunological deficiencies and inflammatory process demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is being researched for a number of neurological diseases, including neuropathic pain, Multiple Sclerosis, and chronic fatigue syndrome.

Technological advancements during the last ten years have improved the accuracy of immunological disease diagnosis. The development of biological tests for identifying and diagnosing immunodeficiency would increase the need for immunoglobulins.

Rising Prevalence of Bleeding Problems to Accelerate Market Growth

Bleeding problems are becoming increasingly frequent. The products of plasma fractionation are used to treat haematological illnesses including haemophilia. Hemophilia is a hereditary bleeding disorder with a diminished capacity for blood clotting that is brought on by a lack of coagulation factor VIII.

Key Challenges encountered by Plasma Fractionation Industry

Development of Recombinant Alternatives to Hamper the Market Growth

The development of recombinant alternatives, the exorbitant cost of advanced items, and unfavorable revenue cycle management are all anticipated to impede the growth of the plasma fractionation market throughout the course of the projection period.

Cancellation of Elective Surgery and Other Health Issues Negatively Affecting the Plasma Fractionation Market

Due to the cancellation of elective surgery and other health issues, the demand for plasma derivatives decreased, offsetting a decrease in the supply of raw materials. As a consequence, despite possible shortages in certain areas, the overall supply of plasma in countries is maintained. The viral pandemic thus had a detrimental effect on the market value for plasma fractionation.

Country-wise Analysis

How will the U.S Perform in the Global Plasma Fractionation Industry Landscape?

Growing Elderly Population and Many Related Disorders to Boost the Market Growth

As per Fact.MR, around 54% of plasma fractionation products are expected to be utilized across North America. Due to the growing elderly population and many related disorders, the United States held the biggest market share in the region.

For instance, the Alzheimer's Association reported in March 2021 that there are currently 13.8 million persons in the United States who are 65 years of age or older and who are living with dementia associated to Alzheimer's disease. Additionally, according to the same source, the number of Americans who died from Alzheimer's and dementia-related causes rose by 16% during the COVID-19 pandemic.

According to estimates, the nation spent around US$ 355 Billion in 2021 on Alzheimer's and other dementia-related expenses, and it is predicted that by 2050, this sum will have increased to more than US$ 1.1 Trillion.

In addition, it is anticipated that 13.5 Million Americans aged 65 and older would have Alzheimer's dementia by the year 2050, up from an expected 6.2 million in 2021. The increasing incidence of Alzheimer's disease and the product's efficacy in treating the condition therefore support the market's expansion during the anticipated timeframe.

How will the Growth of Plasma Fractionation Market Escalate across China?

Increased Government Regulation to Enhance the Market Prospects

The Chinese plasma fractionation market is growing as a result of increased government regulations, favorable public and private funding for research and development, increased use of immunoglobulins, rising prevalence of target diseases among an ageing population with blood-related diseases, and rising adoption of plasma-based therapies. According to Fact.MR, a CAGR of 6.9% is expected for the plasma fractionation market in China.

Country-wise Forecast CAGRs for the Plasma Fractionation Market

Country	CAGR
U.K	6.7%
India	4.5%
South Korea	5.3%
China	6.9%
U.S	7%

Category-wise Insights

Which is the Most Sought-after End-Use Category?

The Hospitals & Clinics Segment to Boost the Market’s Growth

Both in 2021 and during the course of the projection period, the hospitals & clinics segment had the biggest revenue share. The category is predicted to have considerable growth because to the rising off-label usage of plasma fractionation products in hospitals to treat a number of ailments, better infrastructure, and healthcare services provided by hospitals. Furthermore, there is a high demand for plasma fractionation products due to the complicated illnesses that may be addressed in contemporary clinical settings.

Additionally, the market is developing as a result of an increase in surgical operations and the usage of plasma-derived products. Between January 1, 2019, and January 30, 2021, 13 million surgical operations were performed in the US, according to the NCBI. These elements are also anticipated to stimulate market expansion.

Which Segment to Remain Dominant in the Method Category?

Centrifugation Segment to Enhance Growth Prospects

With a share of 33%, centrifugation approach towards plasma fractionation is likely to be the most sought after method. Getting high-quality blood supernatant requires centrifugation. It also helps researchers separate blood consistently, which improves patient clinical results. Thus, the market expansion would be aided by the rising need for centrifugation tools.

The use of purification methods and industrial-scale chromatographic fractionation for plasma fractionation has risen. Coagulation factors, protease inhibitors, and anticoagulants are some of the novel therapeutic plasma products that have been created. As a result, chromatography has enabled the development of novel therapeutics for the treatment of individuals with congenital or acquired abnormalities in plasma protein levels. It will thus encourage market expansion.

Plasma Fractionation Market- Competitive Landscape

To increase their market position, key companies in this market are using a variety of methods, such as alliances through mergers and acquisitions, regional expansion, and strategic collaborations. Some prominent market developments are as follows:

• In May 2022, Terumo Blood and Cell Technologies established its newest production plant in Douglas County, Colorado. The modern production plant, which cost USD $250 million, is in line with the company's goals of improving society via healthcare and servicing more people. In order to supply customers with source plasma collections, the 170,000 square foot facility will create single-use collection sets for the recently FDA-approved Rika Plasma Donation System (Rika).
• In May 2022, according to the National Fractionation Agreement in place between the National Blood Authority and CSL Behring, new facilities were added by CSL Behring at its manufacturing facility in Broadmeadows, Victoria, to increase processing capacity for Australia's expanding annual domestic plasma collections.

Key Segments Covered in the Plasma Fractionation Industry Survey

• By Product :

  • Albumin
  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
    • Others
  • Coagulation Factors
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrates
    • Fibrinogen Concentrates
    • Others
  • Protease Inhibitors
  • Others

• By Method :

  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others

• By Application :

  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Pulmonology
  • Others

• By End User :

  • Hospitals & Clinics
  • Clinical Research
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa